Aurora Cannabis reiterates call for shareholders to reject revised Curaleaf bid

Aurora Cannabis' board reaffirmed its opposition to Curaleaf's revised offer for all outstanding common shares, citing significant undervaluation. The offer, revised October 6, 2026, remains open until December 4, 2026. Higher consideration consists principally of Curaleaf shares; the board warned that a significant portion of cash consideration would come from Aurora's balance sheet. A special committee is exploring third-party transactions or continued independence, with multiple parties reviewing information under confidentiality agreements. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurora Cannabis Inc. published the original content used to generate this news brief via (Ref. ID: 202610141548PR_NEWS_USPR_____TO72573) on October 14, 2026, and is solely responsible for the information contained therein. (C)